One of the world’s leading vaccine makers is partnering with a major artificial intelligence company to advance medicine – and its chief executive is excited.
On Wednesday, Moderna and OpenAI announced their ongoing partnership Deploy AI across Moderna, giving your teams – including legal, research and production – access to ChatGPT Enterprise. The company said Incorporating AI into its business could lend a hand it exceed expectations According to the Wall Street Journal, it will introduce 15 modern products to the market over the next five years.
Stéphane Bancel, Moderna’s chief executive, told the Journal that the partnership will be key to streamlining the vaccine maker’s business process as it moves beyond the Covid-19 vaccine to produce other mRNA drugs that can prevent similar viruses and treat cancer. Bancel told the Journal that he has been obsessed with ChatGPT since its launch in delayed 2022 and that his goal is for Moderna employees to exploit it no less than 20 times a day. He added that employees are joyful to exploit the chatbot in their work.
“Just as the introduction of the personal computer in the 1980s changed the way we work and live, artificial intelligence is on track to completely transform our everyday lives, and OpenAI is helping us lead the way,” Bancel said in statement. “Moderna has an ambitious plan to bring multiple products to market over the next few years, and partnering with companies like OpenAI is critical to our ability to scale and maximize our impact on patients.”
The collaboration between Moderna and OpenAI began in 2023 with a project launching Moderna’s version of ChatGPT called mChat. Since then, Moderna has deployed more than 750 GPTs, or pre-trained generative transformers, to automate its operations, including GPTs tailored to select doses for clinical trials. GPT is a type of Huge Language Model (LLM) developed by OpenAI.
“Moderna is leading the way by enabling all of its employees to exploit AI to solve complicated problems,” Sam Altman, CEO of OpenAI, said in a statement. “We look forward to continuing to work with Moderna to bring next-generation medicines to patients in need.”
